Related Experiment Video

Updated: Mar 7, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K

Comparative Effectiveness of Mycophenolate Mofetil for the Treatment of Juvenile-Onset Proliferative Lupus Nephritis

Simon Y Tian1, Earl D Silverman1, Eleanor Pullenayegum2

  • 1Program of Child Health Evaluative Sciences, The Hospital for Sick Children and The Hospital for Sick Children Research Institute, and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.

Arthritis Care & Research
|February 10, 2017
PubMed

Insights

Mycophenolate mofetil (MMF) improved long-term kidney function in children with proliferative lupus nephritis (PLN). This therapy showed superior outcomes compared to other treatments, maintaining renal function for up to seven years.

Area of Science:

  • Nephrology
  • Pediatric Rheumatology
  • Immunology

Background:

  • Juvenile-onset proliferative lupus nephritis (PLN) is a severe condition with limited clinical trial data on treatment effectiveness.
  • Existing research lacks robust evidence to guide therapeutic choices for pediatric PLN patients.

Purpose of the Study:

  • To evaluate the long-term effectiveness of mycophenolate mofetil (MMF) compared to other therapies for juvenile-onset PLN.
  • To assess the impact of MMF on estimated glomerular filtration rate (GFR) in this cohort.

Main Methods:

  • Utilized prospectively collected data from 172 patients with juvenile-onset PLN (onset age <18 years).
  • Employed marginal structural models to correct for confounding by indication, analyzing long-term renal outcomes.
  • Measured estimated GFR using the revised Schwartz formula over a mean follow-up of approximately 4 years.

Main Results:

  • MMF demonstrated superiority over other therapies, showing a 6% average improvement in estimated GFR.
  • Significant improvements in estimated GFR were observed starting from year 4 in patients treated with MMF.
  • This renal function improvement was sustained throughout the study period, up to 7 years of follow-up.

Conclusions:

  • MMF is more beneficial than alternative therapies for improving and maintaining long-term renal function in juvenile-onset PLN.
  • Findings align with existing evidence from adult PLN clinical trials, supporting MMF's efficacy.
Abstract

More Related Videos

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.6K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
289
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
789
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
304
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
209
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
343
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
618